These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 33560718)
21. Role of volumetric parameters obtained from Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068 [TBL] [Abstract][Full Text] [Related]
22. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367 [TBL] [Abstract][Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
24. Comparison of quantitative whole body PET parameters on [ Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135 [TBL] [Abstract][Full Text] [Related]
26. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223 [TBL] [Abstract][Full Text] [Related]
27. Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma? Can C; Gündoğan C; Kömek H Clin Nucl Med; 2021 Apr; 46(4):e233-e235. PubMed ID: 33031232 [TBL] [Abstract][Full Text] [Related]
29. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. Isik EG; Has-Simsek D; Sanli O; Sanli Y; Kuyumcu S Clin Nucl Med; 2022 Jan; 47(1):e54-e55. PubMed ID: 34392294 [TBL] [Abstract][Full Text] [Related]
30. Response Assessment and Prediction of Progression-Free Survival by Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768 [TBL] [Abstract][Full Text] [Related]
31. Assessing Krenning's score on 68 Ga-DOTATATE PET-CT and miPSMA score on 68 Ga-PSMA-11 PET-CT in TENIS: a comparison with FDG PET/CT and examining the feasibility of targeted radionuclide therapy. Sonavane S; Salvi O; Asopa RV; Basu S Nucl Med Commun; 2024 Aug; 45(8):690-701. PubMed ID: 38832433 [TBL] [Abstract][Full Text] [Related]
33. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376 [TBL] [Abstract][Full Text] [Related]
34. Response assessment using Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186 [TBL] [Abstract][Full Text] [Related]
35. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality. Singh B; Sharma S; Bansal P; Hooda M; Singh H; Parihar AS; Kumar A; Watts A; Mohan R; Singh SK Nucl Med Commun; 2021 May; 42(5):482-489. PubMed ID: 33395191 [TBL] [Abstract][Full Text] [Related]
37. Incidental Detection of Second Primary Thyroid Malignancy in Patients of Metastatic Castration-Resistant Prostate Carcinoma: Documentation on 68 Ga-PSMA-11 and 64 CuCl 2 PET/CT. Nazar A; Kalshetty A; Basu S Clin Nucl Med; 2024 Aug; 49(8):e396-e398. PubMed ID: 38768182 [TBL] [Abstract][Full Text] [Related]
38. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values. Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016 [TBL] [Abstract][Full Text] [Related]
39. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438 [TBL] [Abstract][Full Text] [Related]
40. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2784-2793. PubMed ID: 38635050 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]